Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines. The Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in the areas of cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, pain, and respiratory; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. The Alcon segment offers eye care products, such as eye care devices for cataract, retinal, glaucoma, and refractive surgery, as well as intraocular lenses to treat cataracts and refractive errors; viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery; and contact lenses, as well as contact lens care products, including multi-purpose and hydrogen-peroxide based solutions, rewetting drops, and daily protein removers. Novartis AG has collaboration agreements with Xencor; Surface Oncology; Intellia Therapeutics; Caribou Biosciences; Bristol-Myers Squibb; IBM Watson Health; Amgen; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; and PEAR Therapeutics. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:NVS
CUSIPN/A
Phone41-61-324-1111
Debt
Debt-to-Equity Ratio0.30
Current Ratio1.15
Quick Ratio0.89
Price-To-Earnings
Trailing P/E Ratio17.52
Forward P/E Ratio16.56
P/E Growth1.84
Sales & Book Value
Annual Sales$49.11 billion
Price / Sales3.96
Cash Flow$7.6053 per share
Price / Cash11.02
Book Value$32.03 per share
Price / Book2.62
Profitability
EPS (Most Recent Fiscal Year)$4.81
Net Income$7.70 billion
Net Margins27.06%
Return on Equity16.05%
Return on Assets8.67%
Miscellaneous
Employees121,597
Outstanding Shares2,317,460,000
Market Cap$192.44 billion
Novartis (NYSE:NVS) Frequently Asked Questions
What is Novartis' stock symbol?
Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."
How will Novartis' stock buyback program work?
Novartis declared that its board has authorized a share buyback plan on Saturday, April 8th 2017, which authorizes the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire up to 2.9% of its shares through open market purchases. Shares repurchase plans are often an indication that the company's leadership believes its stock is undervalued.
How were Novartis' earnings last quarter?
Novartis AG (NYSE:NVS) released its quarterly earnings data on Wednesday, July, 18th. The company reported $1.29 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.27 by $0.02. The company earned $13.16 billion during the quarter, compared to the consensus estimate of $12.93 billion. Novartis had a return on equity of 16.05% and a net margin of 27.06%. The business's quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.22 EPS. View Novartis' Earnings History.
When is Novartis' next earnings date?
What price target have analysts set for NVS?
10 brokers have issued 1-year price targets for Novartis' shares. Their forecasts range from $91.00 to $91.00. On average, they anticipate Novartis' stock price to reach $91.00 in the next twelve months. This suggests a possible upside of 8.6% from the stock's current price. View Analyst Price Targets for Novartis.
What is the consensus analysts' recommendation for Novartis?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 1 sell rating, 8 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novartis.
Are investors shorting Novartis?
Novartis saw a increase in short interest in July. As of July 13th, there was short interest totalling 1,796,542 shares, an increase of 77.0% from the June 29th total of 1,014,840 shares. Based on an average daily trading volume, of 1,897,726 shares, the short-interest ratio is presently 0.9 days. Currently, 0.1% of the company's shares are sold short. View Novartis' Current Options Chain.
Who are some of Novartis' key competitors?
Some companies that are related to Novartis include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Sanofi (SNY), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), AstraZeneca (AZN), Bayer (BAYRY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).
Who are Novartis' key executives?
Novartis' management team includes the folowing people:
- Dr. Vasant Narasimhan, Chief Exec. Officer (Age 42)
- Mr. Harry Kirsch, Chief Financial Officer (Age 53)
- Mr. Steven Baert, Head of HR (Age 44)
- Mr. Richard Francis, Chief Exec. Officer of Sandoz (Age 50)
- Dr. James E. Bradner M.D., Pres of Novartis Institutes for Biomedical Research (Age 46)
Has Novartis been receiving favorable news coverage?
News coverage about NVS stock has trended somewhat positive on Wednesday, Accern reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Novartis earned a news and rumor sentiment score of 0.10 on Accern's scale. They also gave media stories about the company an impact score of 46.56 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View Recent Headlines for Novartis.
Who are Novartis' major shareholders?
Novartis' stock is owned by many different of institutional and retail investors. Top institutional investors include Wells Fargo & Company MN (0.33%), Fisher Asset Management LLC (0.32%), Bank of America Corp DE (0.29%), Boston Partners (0.24%), Parnassus Investments CA (0.20%) and Charles Schwab Investment Advisory Inc. (0.17%). Company insiders that own Novartis stock include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Institutional Ownership Trends for Novartis.
Which major investors are selling Novartis stock?
NVS stock was sold by a variety of institutional investors in the last quarter, including Parnassus Investments CA, United Services Automobile Association, Douglass Winthrop Advisors LLC, Bank of New York Mellon Corp, Saturna Capital CORP, FMR LLC, South Texas Money Management Ltd. and Delek Group Ltd.. View Insider Buying and Selling for Novartis.
Which major investors are buying Novartis stock?
NVS stock was purchased by a variety of institutional investors in the last quarter, including Charles Schwab Investment Advisory Inc., Boston Partners, Renaissance Technologies LLC, Fiera Capital Corp, Janus Henderson Group PLC, Fisher Asset Management LLC, Cornerstone Wealth Management LLC and Fort Washington Investment Advisors Inc. OH. Company insiders that have bought Novartis stock in the last two years include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Insider Buying and Selling for Novartis.
How do I buy shares of Novartis?
Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Novartis' stock price today?
One share of NVS stock can currently be purchased for approximately $83.81.
How big of a company is Novartis?
Novartis has a market capitalization of $192.44 billion and generates $49.11 billion in revenue each year. The company earns $7.70 billion in net income (profit) each year or $4.81 on an earnings per share basis. Novartis employs 121,597 workers across the globe.
How can I contact Novartis?
Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 41-61-324-1111 or via email at [email protected]
MarketBeat Community Rating for Novartis (NYSE NVS)
MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote "Outperform" if you believe NVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
